LCI-GI-APX-NIN-001: Nintedanib in Metastatic Appendiceal Carcinoma
Phase of Trial: Phase II
Latest Information Update: 03 Oct 2019
Price : $35 *
At a glance
- Drugs Nintedanib (Primary)
- Indications Appendiceal cancer; Carcinoma
- Focus Therapeutic Use
- 19 Jan 2019 Trial design presented at the 2019 Gastrointestinal Cancers Symposium.
- 31 Aug 2018 Biomarkers information updated
- 26 Feb 2018 Status changed from not yet recruiting to recruiting.